Second-quarter 2009 unaudited results announced by Deltagen

Deltagen, Inc. (Pink Sheets: DGEN), a leading provider of drug discovery tools to the biopharmaceutical industry, today reported unaudited consolidated financial results for the three months ended June 30, 2009.

Revenues: The Company’s consolidated revenues for the three months ended June 30, 2009 totaled $0.282 million. The revenues were attributable primarily to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the Company’s DeltaOne^TM program.

Interest Income: The Company had interest income of $0.004 million for the three months ended June 30, 2009.

Expenses: Total consolidated expenses for the three months ended June 30, 2009 were $0.435 million. The operating expenses were attributable primarily to labor costs and other general and administrative expenses, including $0.078 million in royalty and commission expenses. The labor costs included a cumulative total of $0.052 million paid to the Company’s management team in May 2009, which payment was the last of three installment payments relating to the Company’s May 31, 2007 dividend that were made under the Company’s Management Retention and Incentive Bonus Plan, which is discussed in greater detail in the “Subsequent Events” section of Management’s Discussion and Analysis of Financial Conditions and Results of Operations for the year ended December 31, 2006, which is posted on the Company’s website (www.deltagen.com).

Net Loss: Net loss before provision for income taxes for the three months ended June 30, 2009 was $0.149 million.

Cash, Cash Equivalents and Accounts Receivable: As of June 30, 2009, the Company had $4.702 million in consolidated cash and cash equivalents and $0.221 million in accounts receivable.

Subsequent Events: In July 2009, the Company’s wholly-owned subsidiary, Deltagen Europe, S.A., was dissolved and its cash holdings ($1.392 million) were transferred to the Company’s U.S.-based bank.

The unaudited consolidated financial statements for the second quarter of 2009, accompanying notes, and Management’s Discussion and Analysis of Financial Conditions and Results of Operations for such period will be posted on Deltagen’s website (www.deltagen.com).

www.deltagen.com